Provided by Tiger Trade Technology Pte. Ltd.

AbCellera Biologics

12.39
+1.7816.78%
Volume:9.06M
Turnover:109.16M
Market Cap:4.01B
PE:-22.71
High:12.48
Open:11.00
Low:10.99
Close:10.61
52wk High:12.48
52wk Low:2.75
Shares:324.00M
Float Shares:221.00M
Volume Ratio:1.34
T/O Rate:4.10%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5455
EPS(LYR):-0.4902
ROE:-17.30%
ROA:-10.39%
PB:4.48
PE(LYR):-25.28

Loading ...

Why AbCellera Biologics (ABCL) Is Up 5.5% After New Jazz T-Cell Engager Collaboration Agreement

Simply Wall St.
·
Jun 20

Analysts Offer Insights on Healthcare Companies: Zymeworks (ZYME), Amylyx Pharmaceuticals Inc (AMLX) and AbCellera Biologics (ABCL)

TIPRANKS
·
Jun 18

Jazz Pharma, AbCellera ink antibody deal worth up to $876 million

Reuters
·
Jun 17

Jazz Pharmaceuticals, AbCellera Ink $876 Million Cancer Treatment Pact

Dow Jones
·
Jun 17

Jazz Pharmaceuticals, AbCellera collaborate for TCE multispecific antibodies

TIPRANKS
·
Jun 17

Jazz Pharmaceuticals, AbCellera team up on T-cell engaging multispecific antibodies for GI cancers

Reuters
·
Jun 17

Jazz Pharmaceuticals and Abcellera Announce Collaboration to Discover Next-Generation T-Cell Engaging Multispecific Antibodies

THOMSON REUTERS
·
Jun 17

Abcellera Biologics - Collaboration Includes $56 Mln Upfront and up to $792 Mln Option Fees per Program

THOMSON REUTERS
·
Jun 17

Abcellera Biologics - Jazz Has Exclusive Option to Develop and Commercialize Antibodies From Collaboration

THOMSON REUTERS
·
Jun 17

Is AbCellera (ABCL) Using Boardroom Oncology Talent to Redefine Its Clinical Ambitions?

Simply Wall St.
·
Jun 13

AbCellera shareholders elect John Montalbano, Stephen Quake as Class III directors

Reuters
·
Jun 13

AbCellera files Form 3 for director Victor Sandor, reporting no beneficial ownership

Reuters
·
Jun 12

AbCellera Biologics Adds Victor Sandor to Board

TIPRANKS
·
Jun 06

AbCellera appoints Victor Sandor to board as independent director

Reuters
·
Jun 05

Abcellera Appoints DR. Victor Sandor to Its Board of Directors

THOMSON REUTERS
·
Jun 05

Is AbCellera (ABCL) Turning Upgraded Earnings Forecasts Into a Durable Clinical-Stage Business Model?

Simply Wall St.
·
Jun 04

A Look At AbCellera Biologics (ABCL) Valuation After Improved Earnings Outlook And Sector Outperformance

Simply Wall St.
·
Jun 02

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Hims & Hers Health (HIMS), AbCellera Biologics (ABCL) and Indivior (INDV)

TIPRANKS
·
May 22

AbCellera publishes corporate overview on internal antibody pipeline, platform expansion strategy

Reuters
·
May 20

AbCellera director John S. Montalbano acquires 20,000 common shares for $95,400

Reuters
·
May 19